ZyVersa Therapeutics Inc (ZVSA)
1.08
-0.05
(-4.42%)
USD |
NASDAQ |
Nov 15, 16:00
1.06
-0.02
(-1.85%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.112M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -96.29% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.1289 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions. |
| URL | https://www.zyversa.com |
| Investor Relations URL | https://investors.zyversa.com/ |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions. |
| URL | https://www.zyversa.com |
| Investor Relations URL | https://investors.zyversa.com/ |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |